Roche Notches Up First Approval For CD20xCD3 Bispecific Lunsumio

Positioned As ‘Off-The-Shelf’ Rival To CAR-Ts

 
• By Andrew McConaghie
  
Roche_Basel
Lunsumio and the late-stage glofitamab will complement antibody drug conjugate Polivy in Roche's hemato-oncology portfolio. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip